CalciMedica Q3 net loss narrows 78% to $1.7 million

• CalciMedica’s third-quarter 2026 net loss narrowed 78% year over year to $1.7 million.
• Total other income swung to $3.1 million from a $2.2 million expense a year earlier.
• Cash, cash equivalents and short-term investments totaled $13.8 million at September 30, expected to fund operations into the second half of 2027.
• Auxora pulmonary hypertension trial data and the CM5480 investigational new drug submission are both expected in mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-454430), on November 10, 2026, and is solely responsible for the information contained therein.